Paula
Rodríguez Otero
Consultora Médica
![Foto de Paula](/img/nophoto.png)
![Foto de Policlinico S.Orsola-Malpighi](/img/noimage_org.png)
Policlinico S.Orsola-Malpighi
Bolonia, ItaliaPublicaciones en colaboración con investigadores/as de Policlinico S.Orsola-Malpighi (8)
2024
-
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Future Oncology
2023
-
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
The Lancet Haematology, Vol. 10, Núm. 5, pp. e367-e381
-
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
New England Journal of Medicine, Vol. 388, Núm. 11, pp. 1002-1014
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
2022
2020
-
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial
Leukemia, Vol. 34, Núm. 1, pp. 224-233